Hikma launches Dicyclomine Hydrochloride Oral Solution

London, May 28, 2020 – Hikma Pharmaceuticals PLC (Hikma), the multinational generic pharmaceutical company, has launched Dicyclomine Hydrochloride Oral Solution, USP, 10 mg/5 mL, an AA-rated version of Bentyl® [1] Oral Syrup, 10 mg/5 mL in the United States through its US affiliate, Hikma Pharmaceuticals USA Inc.

Press Release Product 28 May 2020

Hikma’s Dicyclomine Hydrochloride Oral Solution USP was approved with a Competitive Generic Therapy (CGT) designation from the US Food and Drug Administration. Hikma is the “first approved applicant” for this CGT and therefore is eligible for 180 days of CGT exclusivity which began upon commercial marketing of Hikma’s product.

Dicyclomine Hydrochloride Oral Solution is indicated for the treatment of patients with functional bowel/irritable bowel syndrome.

According to IQVIA, US sales of Dicyclomine Hydrochloride Oral Solution USP, 10 mg/5 mL were approximately $3 million in the 12 months ending March 2020.

[1] Bentyl® is a registered trademark of Aptalis Pharma Canada ULC

Important Safety Information for Dicyclomine Hydrochloride Oral Solution, USP, 10 mg/5 mL:



Dicyclomine hydrochloride is contraindicated in infants less than 6 months of age, nursing mothers and in patients with:

  • Unstable cardiovascular status in acute hemorrhage
  • Myasthenia gravis
  • Glaucoma
  • Obstructive uropathy
  • Obstructive disease of the gastrointestinal tract
  • Severe ulcerative colitis
  • Reflux esophagitis


Cardiovascular Conditions

  • Use dicyclomine hydrochloride with caution in patients with conditions characterized by tachyarrhythmia such as thyrotoxicosis, congestive heart failure and in cardiac surgery, where they may further accelerate the heart rate. Investigate any tachycardia before administration of dicyclomine hydrochloride. Care is required in patients with coronary heart disease, as ischemia and infarction may be worsened, and in patients with hypertension.

Peripheral and Central Nervous System (CNS)

  • Peripheral effects of dicyclomine hydrochloride include dryness of the mouth with difficulty in swallowing and talking, thirst, reduced bronchial secretions, dilatation of the pupils (mydriasis) with loss of accommodation (cycloplegia) and photophobia, flushing and dryness of the skin, transient bradycardia followed by tachycardia, with palpitations and arrhythmias, and difficulty in micturition, as well as reduction in the tone and motility of the gastrointestinal tract leading to constipation.

In the presence of high environmental temperature, heat prostration can occur with drug use. Use with caution in patients with fever. If symptoms occur, the drug should be discontinued and supportive measures instituted. Use with caution in patients with autonomic neuropathy.

CNS signs and symptoms include confusion, disorientation, short-term amnesia, hallucinations, dysarthria, ataxia, coma, euphoria, fatigue, insomnia, agitation and mannerisms and inappropriate affect. Psychosis has been reported in sensitive individuals given anticholinergic drugs.

Dicyclomine hydrochloride may produce drowsiness, dizziness or blurred vision. Warn the patient not to engage in activities requiring mental alertness, such as operating a motor vehicle or other machinery or performing hazardous work while taking dicyclomine hydrochloride.

Myasthenia Gravis

With overdosage, a curare-like action may occur. Do not give dicyclomine hydrochloride to patients with myasthenia gravis except to reduce adverse muscarinic effects of an anticholinesterase.

Intestinal Obstruction

Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance, treatment with this drug would be inappropriate and possibly harmful.

Rarely, development of Ogilvie’s Syndrome has been reported.

Toxic Dilatation of Intestinemegacolon

Toxic dilatation of intestine and intestinal perforation is possible when anticholinergic agents are administered in patients with Salmonella dysentery.

Ulcerative Colitis

Use with caution in patients with ulcerative colitis. Large doses may suppress intestinal motility to the point of producing a paralytic ileus and the use of this drug may precipitate or aggravate the serious complication of toxic megacolon. Contraindicated in patients with severe ulcerative colitis.

Prostatic Hypertrophy

Use with caution in patients with known or suspected prostatic enlargement.

Hepatic and Renal Disease

Use with caution in patients with known hepatic and renal impairment.

Geriatric Population

Use with caution in elderly patients who may be more susceptible to its adverse effects.


The pattern of adverse effects seen with dicyclomine hydrochloride is dose-related and usually reversible when treatment is discontinued.

The most serious adverse reactions reported include cardiovascular and CNS symptoms.


Antiglaucoma Agents

Anticholinergics antagonize the effects of antiglaucoma agents. Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. Use of dicyclomine hydrochloride in patients with glaucoma is not recommended.

Other Drugs With Anticholinergic Activity

Amantadine, antiarrhythmic agents of Class I, antihistamines, antipsychotic agents, benzodiazepines, MAO inhibitors, narcotic analgesics, nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants and other drugs having anticholinergic activity may increase certain actions or side effects of anticholinergic drugs, including dicyclomine hydrochloride.

Other Gastrointestinal Motility Drugs

Interaction with other gastrointestinal motility drugs may antagonize the effects of drugs that alter gastrointestinal motility.

Effect of Antacids

Simultaneous use of dicyclomine hydrochloride and antacids should be avoided.

Effect of Absorption of Other Drugs

Anticholinergic agents may affect gastrointestinal absorption of various drugs by affecting gastrointestinal motility, such as slowly dissolving dosage forms of digoxin; increased serum digoxin concentration may result.

Effect on Gastric Acid Secretion

The inhibiting effects of anticholinergic drugs on gastric hydrochloric acid secretion are antagonized by agents used to treat achlorhydria and those used to test gastric secretion.



Pregnancy Category B

Adequate and well-controlled studies have not been conducted with dicyclomine hydrochloride in pregnant women at the recommended doses of 80 to 160 mg/day. This drug should be used during pregnancy only if clearly needed.

Nursing Mothers

Dicyclomine hydrochloride is contraindicated in women who are breastfeeding.

Pediatric Use

Dicyclomine hydrochloride is contraindicated in infants younger than 6 months of age. Safety and effectiveness in other pediatric patients have not been established.

Geriatric Use

Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range in adults, reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy.

Because elderly patients are more likely to have decreased renal function, care should be taken to determine the appropriate dose. Renal function should be monitored.

Patients with Renal Impairment

Effects of renal impairment on pharmacokinetics (PK), safety and efficacy of dicyclomine hydrochloride have not been studied. However, dicyclomine hydrochloride is known to be substantially excreted by the kidney and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Administer with caution in these patients.

Patients with Hepatic Impairment

Effects of renal impairment on PK, safety and efficacy of dicyclomine hydrochloride have not been studied. Administer with caution in patients with hepatic impairment.


Dosage must be adjusted to individual patient needs. If efficacy is not achieved within 2 weeks or side effects require doses below 80 mg/day, the drug should be discontinued. Documented safety data are not available for doses above 80 mg/day for periods longer than 2 weeks.


For more information, please see the full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit https://www.fda.gov/medwatch or call 1-800-FDA-1088.

Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228

Distributed by: Hikma Pharmaceuticals USA Inc., Eatontown, NJ 07724

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.